PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19744978-12 2009 Daptomycin was bactericidal against hVISA strains. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 36-41 17531446-7 2007 Daptomycin MIC and MBC values were slightly higher for the hVISA isolates compared with WT-MRSA, with MBC/MIC ratios of only 1-2 for both groups. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 59-64 19838095-8 2009 The thickness of bacterial cell-wall recognized in h-VISA strains can represent a physical and electrical barrier to reach both the vancomycin and daptomycin target site. Daptomycin 147-157 mitochondrial antiviral signaling protein Homo sapiens 53-57 18984644-9 2009 Daptomycin was bactericidal against both MRSA and hVISA isolates, although the rate of kill was slower against hVISA. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 50-55 18984644-9 2009 Daptomycin was bactericidal against both MRSA and hVISA isolates, although the rate of kill was slower against hVISA. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 111-116 18984644-10 2009 CONCLUSIONS: Overall, daptomycin achieved rapid and effective kill against both MRSA and hVISA while vancomycin displayed slow and minimal kill against MRSA and minimal-to-no activity against hVISA, regardless of high dose exposure. Daptomycin 22-32 mitochondrial antiviral signaling protein Homo sapiens 89-94 17531446-10 2007 Daptomycin was demonstrated to have excellent in vitro activity when tested against Gram-positive isolates collected from Asia-Pacific countries, including hVISA strains. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 156-161 24329974-12 2014 The MIC to daptomycin was higher in hVISA (0.75 mug/mL vs. 0.32 mug/mL, p 0.049). Daptomycin 11-21 mitochondrial antiviral signaling protein Homo sapiens 36-41 16801409-3 2006 All MRSA-WT and hVISA strains were inhibited by < or = 1 microg/ml of daptomycin, while the VISA strains showed slightly higher daptomycin MICs (range, 0.5 to 4 microg/ml). Daptomycin 73-83 mitochondrial antiviral signaling protein Homo sapiens 16-21 16801409-3 2006 All MRSA-WT and hVISA strains were inhibited by < or = 1 microg/ml of daptomycin, while the VISA strains showed slightly higher daptomycin MICs (range, 0.5 to 4 microg/ml). Daptomycin 73-83 mitochondrial antiviral signaling protein Homo sapiens 17-21 26320398-11 2016 Compared with vancomycin-susceptible S. aureus, hVISA and VISA isolates were less susceptible to ciprofloxacin, clindamycin, daptomycin, gentamicin, rifampin, and trimethoprim/sulfamethoxazole, and are thus, more likely to have SCCmec II or III element. Daptomycin 125-135 mitochondrial antiviral signaling protein Homo sapiens 48-53 26320398-11 2016 Compared with vancomycin-susceptible S. aureus, hVISA and VISA isolates were less susceptible to ciprofloxacin, clindamycin, daptomycin, gentamicin, rifampin, and trimethoprim/sulfamethoxazole, and are thus, more likely to have SCCmec II or III element. Daptomycin 125-135 mitochondrial antiviral signaling protein Homo sapiens 49-53 26430942-6 2015 Population analysis profile-area under curve analysis confirmed hVISA in 4.5% (9/198), 6.5% (8/123), and 6.7% (12/179) in respective years; 24% (7/29) of hVISA isolates were nonsusceptible to daptomycin. Daptomycin 192-202 mitochondrial antiviral signaling protein Homo sapiens 64-69 26430942-6 2015 Population analysis profile-area under curve analysis confirmed hVISA in 4.5% (9/198), 6.5% (8/123), and 6.7% (12/179) in respective years; 24% (7/29) of hVISA isolates were nonsusceptible to daptomycin. Daptomycin 192-202 mitochondrial antiviral signaling protein Homo sapiens 154-159 26143590-10 2015 Whilst further investigation is needed, it can be hypothesised that MRSA strains become hVISA during prolonged bacteraemia, which may predispose to the development of daptomycin resistance. Daptomycin 167-177 mitochondrial antiviral signaling protein Homo sapiens 88-93 24329974-21 2014 Caution should be employed in the empirical use of daptomycin in hVISA patients. Daptomycin 51-61 mitochondrial antiviral signaling protein Homo sapiens 65-70 22253738-8 2012 Daptomycin can also induce a charge repulsion mechanism both in hVISA and VISA increasing the activity of the mprF. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 64-69 24217694-7 2014 Prior exposure of vancomycin at 1 g q12h reduced the initial microbiological response of daptomycin, particularly for hVISA and VISA isolates, but did not affect the response of ceftaroline. Daptomycin 89-99 mitochondrial antiviral signaling protein Homo sapiens 118-123 24217694-7 2014 Prior exposure of vancomycin at 1 g q12h reduced the initial microbiological response of daptomycin, particularly for hVISA and VISA isolates, but did not affect the response of ceftaroline. Daptomycin 89-99 mitochondrial antiviral signaling protein Homo sapiens 119-123 24325260-14 2013 Daptomycin was found to be highly active against MRSA isolates including hVISA. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 73-78 22495870-5 2012 To our knowledge, this article describes the first case of daptomycin-resistant heterogenous vancomycin intermediate-resistant Staphylococcus aureus (hVISA) in an 82-year-old man undergoing elective total knee arthroplasty in Queensland, Australia, with a subsequent deep prosthetic joint infection.A literature review is presented, and the increasing number of multi-resistant organisms and their implications for orthopedics are discussed. Daptomycin 59-69 mitochondrial antiviral signaling protein Homo sapiens 150-155 22253738-0 2012 Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. Daptomycin 38-48 mitochondrial antiviral signaling protein Homo sapiens 128-133 22253738-0 2012 Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains. Daptomycin 38-48 mitochondrial antiviral signaling protein Homo sapiens 129-133 22253738-5 2012 Our results show that hVISA and VISA present common features that distinguish them from Vancomycin-Susceptible Staphylococcus aureus (VSSA), responsible for the intermediate glycopeptide resistance i.e. an increased cell-wall turnover, an increased positive cell-wall charge responsible for a repulsion mechanism towards vancomycin and daptomycin, and reduced agr-functionality. Daptomycin 336-346 mitochondrial antiviral signaling protein Homo sapiens 22-27 22253738-5 2012 Our results show that hVISA and VISA present common features that distinguish them from Vancomycin-Susceptible Staphylococcus aureus (VSSA), responsible for the intermediate glycopeptide resistance i.e. an increased cell-wall turnover, an increased positive cell-wall charge responsible for a repulsion mechanism towards vancomycin and daptomycin, and reduced agr-functionality. Daptomycin 336-346 mitochondrial antiviral signaling protein Homo sapiens 23-27 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 57-62 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 58-62 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 67-71 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 148-153 22253738-7 2012 Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways responsible for the intermediate vancomycin resistance in VISA. Daptomycin 15-25 mitochondrial antiviral signaling protein Homo sapiens 67-71 22253738-8 2012 Daptomycin can also induce a charge repulsion mechanism both in hVISA and VISA increasing the activity of the mprF. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 65-69 21393156-0 2011 Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 80-84 21321148-3 2011 Three clinical MRSA isolates, including one heterogeneous vancomycin-intermediate S. aureus (hVISA) isolate and one vancomycin-intermediate S. aureus (VISA) isolate, were exposed to daptomycin at 10 or 6 mg/kg of body weight/day for 8 days using a starting inoculum of ~10(9) CFU/g of vegetations, with dose escalation and de-escalation initiated on the fourth day. Daptomycin 182-192 mitochondrial antiviral signaling protein Homo sapiens 93-98 21321148-3 2011 Three clinical MRSA isolates, including one heterogeneous vancomycin-intermediate S. aureus (hVISA) isolate and one vancomycin-intermediate S. aureus (VISA) isolate, were exposed to daptomycin at 10 or 6 mg/kg of body weight/day for 8 days using a starting inoculum of ~10(9) CFU/g of vegetations, with dose escalation and de-escalation initiated on the fourth day. Daptomycin 182-192 mitochondrial antiviral signaling protein Homo sapiens 94-98 21393156-0 2011 Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 104-108 21393156-0 2011 Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. Daptomycin 0-10 mitochondrial antiviral signaling protein Homo sapiens 110-115 21393156-5 2011 RESULTS: The percentage of daptomycin non-susceptible isolates was 0% for vancomycin-susceptible S. aureus (VSSA) (Etest and BMD), for hVISA it was 26% by Etest and 15% by BMD, and for VISA 62% by Etest and 38% by BMD. Daptomycin 27-37 mitochondrial antiviral signaling protein Homo sapiens 136-140 21393156-6 2011 Population analysis profile testing demonstrated daptomycin heteroresistance among the hVISA and VISA strains tested. Daptomycin 49-59 mitochondrial antiviral signaling protein Homo sapiens 87-92 21393156-6 2011 Population analysis profile testing demonstrated daptomycin heteroresistance among the hVISA and VISA strains tested. Daptomycin 49-59 mitochondrial antiviral signaling protein Homo sapiens 88-92 21393156-7 2011 CONCLUSIONS: This is the highest rate of daptomycin non-susceptibility reported among hVISA isolates to date. Daptomycin 41-51 mitochondrial antiviral signaling protein Homo sapiens 86-91 21393156-8 2011 Clinicians should exhibit caution when using daptomycin in situations where serious hVISA or VISA infection is a possibility. Daptomycin 45-55 mitochondrial antiviral signaling protein Homo sapiens 84-89 21393156-8 2011 Clinicians should exhibit caution when using daptomycin in situations where serious hVISA or VISA infection is a possibility. Daptomycin 45-55 mitochondrial antiviral signaling protein Homo sapiens 85-89